Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metsera
Developing next-gen obesity therapies
Biotech
Pfizer axes ex-Metsera obesity asset and GIPR prospect
Pfizer dropped a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Nick Paul Taylor
Aug 4, 2026 8:47am
ADA: Pfizer pads case for berobenatide in obesity
Jun 6, 2026 9:29am
Pfizer links monthly GLP-1 to competitive weight loss in phase 2
Feb 3, 2026 8:45am
With 200 JPM meetings, Novo BD head seeks out the next Metsera
Jan 27, 2026 5:25pm
Pfizer finalizes Metsera buy after contentious Novo bidding war
Nov 13, 2025 12:43pm
Pfizer beats out Novo with $10B agreement to buy Metsera
Nov 8, 2025 8:11am
